Current oncology最新文献_第2页

Approaches to Reduce Toxicity in Pediatric Brain Tumors. 降低小儿脑肿瘤毒性的方法。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-15 DOI: 10.3390/curroncol32050281

Hallie Coltin, Christina Coleman, Chantel Cacciotti

引用次数: 0

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium. 在尿路上皮癌中，Enfortumab Vedotin的机制见解和未来方向：来自Leo & Anne Albert研究所第10届年度膀胱癌护理和研究研讨会的亮点。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-14 DOI: 10.3390/curroncol32050278

Catherine C Fahey, Sean Clark-Garvey, Sima Porten, Ashish M Kamat, Thomas W Flaig, John A Taylor, William Y Kim, Matthew I Milowsky

引用次数: 0

From Algorithms to Insight: The Transformative Power of Artificial Intelligence and Machine Learning in Urological Cancer Research. 从算法到洞察：人工智能和机器学习在泌尿系统癌症研究中的变革力量。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-14 DOI: 10.3390/curroncol32050277

Matthias May, Sabine Brookman-May, Emily Rinderknecht

引用次数: 0

The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma. OLFM4与头颈部鳞状癌进展和顺铂耐药的关系

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-13 DOI: 10.3390/curroncol32050276

Xinlu He, Xi Yao, Keling Pang, Xulin Chen, Zhengbo Wei, Ying Xie

{"title":"The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma.","authors":"Xinlu He, Xi Yao, Keling Pang, Xulin Chen, Zhengbo Wei, Ying Xie","doi":"10.3390/curroncol32050276","DOIUrl":"https://doi.org/10.3390/curroncol32050276","url":null,"abstract":"Head and neck squamous cell carcinoma (HNSCC) is a highly prevalent malignant tumor globally with a poor prognosis. Despite continuous advancements in treatment modalities, the molecular mechanisms underlying its progression and chemotherapy resistance remain unclear. In previous studies, cisplatin drug induction was performed on HNSCC patient-derived tumor organoids (HNSCC-PDOs), successfully establishing a cisplatin-resistant organoid model (HNSCC-PDOcisR). This study conducted RNA sequencing on cisplatin-resistant HNSCC-PDOcisR and their parental PDOs. Bioinformatic analysis revealed that the oncoprotein olfactomedin 4 (OLFM4) was significantly upregulated in the drug-resistant model. Combined analysis of TCGA and CPTAC databases demonstrated that OLFM4 expression correlates with poor clinical prognosis in HNSCC. In vitro cellular experiments verified that OLFM4 overexpression significantly enhanced HNSCC cell proliferation, migration, and invasion capabilities (p < 0.05), while OLFM4 knockdown inhibited these phenotypes. Additionally, OLFM4 was found to mediate cisplatin resistance by regulating levels of reactive oxygen species (ROS), malondialdehyde (MDA), and ferrous ions (Fe2⁺), suppressing cisplatin-induced oxidative stress and ferroptosis while maintaining mitochondrial membrane potential. This study confirms that OLFM4 enhances tumor cell proliferation, migration, and resistance to cisplatin-induced cell death, thereby promoting HNSCC progression. These findings suggest OLFM4 may serve as a prognostic biomarker for HNSCC and a potential therapeutic target to reverse cisplatin resistance in HNSCC.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Registered Dietitians in Cancer Palliative Care: Responsibilities, Challenges, and Interdisciplinary Collaboration-A Cross-Sectional Survey. 注册营养师在癌症姑息治疗中的作用：责任、挑战和跨学科合作——一项横断面调查。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-12 DOI: 10.3390/curroncol32050275

Saori Koshimoto, Koji Amano, Naoharu Mori, Atsuko Imai, Manami Sasaki, Miho Miyajima, Takashi Takeuchi

{"title":"The Role of Registered Dietitians in Cancer Palliative Care: Responsibilities, Challenges, and Interdisciplinary Collaboration-A Cross-Sectional Survey.","authors":"Saori Koshimoto, Koji Amano, Naoharu Mori, Atsuko Imai, Manami Sasaki, Miho Miyajima, Takashi Takeuchi","doi":"10.3390/curroncol32050275","DOIUrl":"https://doi.org/10.3390/curroncol32050275","url":null,"abstract":"Registered dietitians (RDs) in palliative care help maintain patients' quality of life by providing personalized nutritional support that alleviates eating-related distress. This study aimed to clarify the role of RDs in palliative care by examining their responsibilities and challenges in caring for cancer patients. A nationwide mailed survey was conducted in 2022, focusing on RDs involved in cancer palliative care. One RD per facility was included from all 501 hospitals accredited by Japan's Ministry of Health, Labour and Welfare. Multivariate analysis identified factors related to collaboration with palliative care teams and challenges in cancer care. Responses from 325 RDs (63.9%) across 325 hospitals (63.9%) were analyzed. Among RDs who consistently collaborated with the palliative care team (PCT), significant associations (p < 0.05) were found with exclusive engagement in cancer/palliative care, providing nutritional counseling to inpatients, the frequency of ward rounds, and individualized meal provision. Challenges included the following: \"I struggled with determining appropriate food choices for patients unable to eat\", and \"Metabolic complications like cachexia hindered my ability to provide adequate support\". RDs play a crucial role in providing individualized meals for cancer patients through PCT collaboration and ward rounds. To ensure effective support in challenging situations, RDs must be exclusively engaged in palliative care and receive specialized education.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario. 加拿大去分化脂肪肉瘤（DDLPS）的流行病学、治疗模式、生存、医疗资源利用和成本：一项使用安大略省管理数据库的回顾性队列研究

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-09 DOI: 10.3390/curroncol32050273

Soo Jin Seung, Anisia Wong, Raymond Milan, Nisha Chandran, Albiruni R Abdul Razak

{"title":"Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.","authors":"Soo Jin Seung, Anisia Wong, Raymond Milan, Nisha Chandran, Albiruni R Abdul Razak","doi":"10.3390/curroncol32050273","DOIUrl":"https://doi.org/10.3390/curroncol32050273","url":null,"abstract":"Background: Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada.Methods: A retrospective cohort study was conducted among DDLPS patients between 2010 and 2022 using administrative databases. Overall survival, all-cause HCRU, and costs (2023 Canadian dollars, CAD) were compared based on advanced disease and resection status.Results: The overall incidence and cumulative prevalence of DDLPS was 0.465 and 1.995 per 100,000 people, respectively. Of all 611 DDLPS cases (64.3% male, median age [IQR]: 67 [57-76] years), 40.3% and 61.0% had advanced and unresected disease, respectively. The median overall survival (mOS) was 69 months [IQR = 15-151] for the entire cohort, but this was significantly lower for advanced and unresected disease (p < 0.0001). Among patients receiving systemic treatments (N = 117), 81.2% were prescribed doxorubicin as first-line treatment. All-cause healthcare costs (2023 CAD) amounted to CAD 34,448 per person-year (PPY), with inpatient hospitalizations being the highest cost driver at CAD 14,522 PPY and 0.8 inpatient hospitalization PPY for all years. Advanced disease had higher HCRU and costs.Conclusions: This is the first comprehensive real-world evidence study that quantifies the high mortality and cost burden associated with DDLPS in Canada.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Profiling in Non-Small-Cell Lung Cancer: A Single-Center Study on Prevalence and Prognosis. 非小细胞肺癌的分子分析：患病率和预后的单中心研究。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-09 DOI: 10.3390/curroncol32050274

Mustafa Özgür Arıcı, Bora Demirkan, Ebru Taştekin, Derya Kıvrak Salim

{"title":"Molecular Profiling in Non-Small-Cell Lung Cancer: A Single-Center Study on Prevalence and Prognosis.","authors":"Mustafa Özgür Arıcı, Bora Demirkan, Ebru Taştekin, Derya Kıvrak Salim","doi":"10.3390/curroncol32050274","DOIUrl":"https://doi.org/10.3390/curroncol32050274","url":null,"abstract":"The aim of this study is to evaluate the prognostic value of molecular profiling in patients with metastatic non-small-cell lung cancer (NSCLC). This single-center study included patients diagnosed and treated between July 2020 and April 2024. The molecular profiles of patients detected by either next-generation sequencing or conventional methods were reviewed retrospectively. Survival analyses were conducted based on the targetable alterations and treatments received. Seventy patients were included, with a median age of 65 years and a median overall survival (OS) of 13 months. Of all patients, 56 (80%) had at least one molecular alteration, and the most frequent alteration was TP53 (52.9%), followed by KRAS (20%) and EGFR (8.6%). Eighteen patients (25.7%) had an alteration amenable to targeted therapy. Patients who could reach a matched targeted therapy at any treatment line exhibited a longer median OS compared to those who could not (not reached vs. 6.9 months, p = 0.042). Patients with a targetable alteration for first-line treatment demonstrated a longer progression-free survival compared to those without a targetable alteration (not reached vs. 4.9 months, p = 0.006). According to current guidelines, conducting molecular testing to identify all potential targetable alterations in NSCLC is the cornerstone of the treatment decision process. The survival analysis in this study emphasized the impact of the use of targeted therapies on the survival outcomes.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report. 奥西替尼联合布加替尼治疗EGFR三突变肺腺癌1例

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-07 DOI: 10.3390/curroncol32050270

Daphnée Demers, Marie Florescu

引用次数: 0

Impact of Multileaf Collimator Width and Normal Tissue Objective on Radiation Dose Distribution in Stereotactic Radiosurgery Using HyperArc for Single Brain Lesions. 多叶准直器宽度和正常组织物镜对超弧立体定向放射治疗单脑病变放射剂量分布的影响。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-07 DOI: 10.3390/curroncol32050272

Se An Oh, Jae Won Park, Ji Woon Yea, Jaehyeon Park, Yoon Young Jo

{"title":"Impact of Multileaf Collimator Width and Normal Tissue Objective on Radiation Dose Distribution in Stereotactic Radiosurgery Using HyperArc for Single Brain Lesions.","authors":"Se An Oh, Jae Won Park, Ji Woon Yea, Jaehyeon Park, Yoon Young Jo","doi":"10.3390/curroncol32050272","DOIUrl":"https://doi.org/10.3390/curroncol32050272","url":null,"abstract":"This study retrospectively investigated the impact of stereotactic radiosurgery (SRS) normal tissue objective (NTO) and multileaf collimator (MLC) width on radiation dose distribution in patients with brain metastasis treated using HyperArc. In total, 21 patients who underwent SRS using the HyperArc of the TrueBeam linear accelerator from November 2022 to June 2024 were included. All patients received radiotherapy with HASH planned with SRS NTO and HD MLC. HyperArc(HAAH) combined with the auto NTO and HD MLC and HyperArc(HAAM) with auto NTO and millennium MLC were generated and compared. Monitor units (MU), conformity index (CI), radical dose homogeneity index (rDHI), moderate DHI (mDHI), and gradient index (GI) were evaluated as target factors, and V2(Gy), V10(Gy), V12(Gy), V18(Gy), V10(cc), and V12(cc) were evaluated as normal brain factors. Dosimetric comparisons were performed between HASH, HAAH, and HAAM and between target and normal brain tissues. Between HASH and HAAH, average MU was 7206 and 5798, respectively; the difference was significant (p < 0.001). The MU of HAAM was 5835. Among HASH, HAAH, and HAAM, CI and mDHI were not significantly different, but there were significant differences in rDHI, GI, and normal brain tissues. When treating a single lesion using HyperArc, SRS NTO influences MU and GI, and the MLC width influences rDHI and GI. In HyperArc for single metastatic brain lesions, SRS NTO and MLC width have a significant effect on the radiation dose delivered to the target and normal brain tissues.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug Sensitivity Testing in Osteosarcoma: A Case Report. 骨肉瘤药物敏感性试验1例报告。

IF 2.8 4区医学

Current oncology Pub Date : 2025-05-07 DOI: 10.3390/curroncol32050271

Ines Lohse, Giselle Dutcher, Hassan Al-Ali, Warren Alperstein, Donald W Coulter, Matteo Trucco, Jonathan C Trent, Claes Wahlestedt

{"title":"Drug Sensitivity Testing in Osteosarcoma: A Case Report.","authors":"Ines Lohse, Giselle Dutcher, Hassan Al-Ali, Warren Alperstein, Donald W Coulter, Matteo Trucco, Jonathan C Trent, Claes Wahlestedt","doi":"10.3390/curroncol32050271","DOIUrl":"https://doi.org/10.3390/curroncol32050271","url":null,"abstract":"Precision medicine approaches using ex-vivo drug sensitivity testing (DST) have received attention in the cancer research community as a means to improve treatment stratification in populations where multiple treatment attempts are not feasible, or no standard-of-care treatment exists, such as ultra-rare cancers with a significant clinical need for effective treatment options, like osteosarcoma. DST has the potential to supplement existing patient stratification approaches by providing tumor-specific response data to aid in treatment selection at the time of treatment decision. We present the case of a pediatric osteosarcoma patient who was evaluated using DST at the time of standard-of-care treatment to evaluate treatment sensitivity. The DST screen indicated significant treatment sensitivity to anthracyclines and methotrexate, consistent with the first-line standard-of-care therapy (MAP). Clinical follow-up showed treatment sensitivity to standard-of-care MAP treatment and pathology results of 90% necrosis. The present case shows that DST screening is feasible from a technical standpoint, can be performed in a clinically relevant time frame that does not delay treatment start, and provides personalized drug sensitivity information on clinically available agents, and the DST results align with the clinical treatment response.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0